Antigen Vaccines

Tumor Cells – Creative BiolabsAntigen vaccines use tumor-specific antigens (proteins displayed on a tumor cell) to stimulate the immune system. By injecting these antigens into the cancerous area of the patient, the immune system will produce an increased number of antibodies or cytotoxic T lymphocytes, also known as killer T cells, to attack cancer cells that carry that specific antigen. Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for antigen-based vaccines. We guarantee the finest results for our customers all over the world.

Vast amounts of antigen can be created in laboratories. Some antigens are specific for a certain type of cancer; others may induce an immune response in several cancers. Several antigen-based vaccines are being studied including kidney cancer, pancreatic cancer, melanoma, ovarian cancer, breast cancer, prostate cancer, and colorectal cancer. Multiple antigens can be used in this type of vaccine to vary the immune system response.

Peptide or Protein Based Vaccines

Peptide vaccines have turned out to be the most successful approach so far for melanoma, using either free peptides or peptides coated on dendritic cells. They have the feature of focusing the immune response on specific epitopes, of particular advantage for the many tumor antigens that are self antigens. In the case of mutant molecules unique to the tumor, peptides also have the advantage of targeting only the mutant epitope that identifies the tumor cells and avoiding other parts of the antigen that would be present in normal cells. Peptides are also relatively easy to modify so that panels of variants can be studied to increase affinity for the relevant Major Histocompatibility Complex (MHC) molecules, to make the peptides more immunogenic, a process we have termed epitope enhancement. Likewise, the peptide sequence can be modified also to increase the affinity of the peptide-MHC complex for the T cell receptor.

Polyepitope Vaccine Technology

The development of effective peptide-based vaccines for use in humans is complex, requiring the presence of peptides presented across a broad range of human HLA types. Defining and employing multiple CTL epitopes providing broad specificity offers a viable alternative that avoids possible effects associated with toxicity, oncogenicity, and the poor immunogenicity of some full-length antigens. One technique currently under development for the treatment of a number of human diseases involves the construction of a polypeptide that links consecutive CTL epitopes together to produce a polyepitope. The first study to demonstrate that a polyepitope without flanking sequences could be used effectively employed a polypeptide encoded by a recombinant vaccinia virus (VV) vector and expressing nine epitopes derived from Epstein–Barr virus (EBV) that were recognized by six different HLA molecules. The EBV polypeptide was shown to be capable of presenting the epitopes to CTL clones and could be used to expand specific CTLs from peripheral blood mononuclear cells (PBMCs) of EBV-positive individuals. Creative Biolabs has also extended the use of this technology to other human diseases, include infectious pathogens (e.g., HIV, HBV, HCV, malaria) and human malignancies (e.g., melanoma, breast cancer, and cervical cancer).

Undefined Antigen Based Vaccines

A rationale for using undefined antigen vaccines to treat patients with cancer is that for the most common types of malignancy, e.g. carcinomas of epithelial origin, tumor antigens have not been well-characterized. Furthermore, in contrast to defined antigen vaccines, vaccines using intact tumor cells, or preparations derived from whole tumor cells, contain not only shared tumor antigens, but also many TSA, to which the host may not have developed tolerance.

We provide development strategies that use undefined or ill-defined antigen preparations derived from whole tumor cells as the cancer vaccines, including whole tumor cells (both autologous and allogeneic), gene-modified cells (genes encoding cytokines, chemokines, and costimulatory molecules), cell-derived materials (lysates, apoptotic bodies, exosomes, heat shock proteins), and tumor-APC fusion cells.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.


Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket